Clinical Intelligence/Clinical Efficiency

Novel Drug Binders Developer RayzeBio Secures $108 Million


–Total raise of $258 million since company launch in August 2020–

RayzeBio, Inc., which is discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, today announced a $108 million Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X. Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.

“The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated,” said Ken Song, M.D., president and CEO of RayzeBio. “The interest and confidence from our exceptional group of investors that has funded the company enables us to fully invest in our plans to be the leader in targeted radiopharmaceuticals for a multitude of cancer types.”

With over $258 million of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to

Related posts

Clinical Intelligence Co. Pfizer Announces Investor Relations Leader

Business Wire

Apollo Therapeutics Completes $145 Million Financing

Business Wire

Clinical AI Technology Leader Mendel Raises $18M in New Capital

Business Wire